Month: June 2020

DPW Holdings Announces That Construction Has Resumed on Luxury Hotel in Tribeca

Written by Customer Service on June 12, 2020. Posted in Public Companies.

Newport Beach, Cal., June 12, 2020 (GLOBE NEWSWIRE) — DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company (“DPW,” or the “Company”) announced that construction has resumed on the Tribeca Hotel at 456 Greenwich Street, New York, NY. The Company is a limited partner in the Tribeca Hotel development project (the “NY Partnership”). On June 8, 2020, Governor Cuomo announced that construction can resume in New York City, including projects considered non-essential, lifting restrictions previously implemented due to the COVID-19 pandemic.Background on the NY PartnershipOn June 8, 2018, the Company entered into a limited partnership agreement, in which it agreed to become a limited partner in the NY Partnership and has invested an aggregate of $1,869,000. On June 12, 2019, the agreement was restructured whereby DPW has...

Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty

Written by Customer Service on June 12, 2020. Posted in Public Companies.

– Royalty Pharma Acquires Rights to Agios’ Royalty on IDHIFA® Worldwide Net Sales and Outstanding Regulatory Milestone Payments –CAMBRIDGE, Mass. and NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, and Royalty Pharma today announced that Agios has sold its tiered, sales-based royalty rights on worldwide net sales of Bristol Myers Squibb’s IDHIFA® (enasidenib), as well as its rights to receive up to $55 million in outstanding regulatory milestone payments from Bristol Myers Squibb, to Royalty Pharma for $255 million. Agios will continue to co-promote IDHIFA® and receive reimbursement from Bristol Myers Squibb for this co-promotion under its 2010 collaboration agreement with Celgene, a wholly owned subsidiary...

Amphastar Pharmaceuticals to Present at the Raymond James Virtual 2020 Human Healthcare Innovation Conference

Written by Customer Service on June 12, 2020. Posted in Public Companies.

RANCHO CUCAMONGA, Calif., June 12, 2020 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs and Clinical Operations will be presenting at the Raymond James Virtual 2020 Human Healthcare Innovation Conference on Thursday, June 18, 2020 at 11:40 a.m. Eastern Time.This presentation will be made available with a live webcast and may be accessed by visiting Amphastar’s Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 90 days following the presentation.About Amphastar:Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic...

Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting

Written by Customer Service on June 12, 2020. Posted in Public Companies.

57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up13.7 months median OS in patients receiving 3 or more cycles of therapy with 9.7 months duration of follow-upBOSTON, June 12, 2020 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced the oral presentation of updated data from its French Phase 1b/2 clinical trial at the 25th European Hematology Association Annual Meeting (EHA). The trial is evaluating the safety and efficacy of APR-246 (eprenetapopt) in combination with azacitidine (AZA) for the treatment of TP53 mutant myelodysplastic syndromes...

Hooker Furniture Reports Preliminary Results for First Quarter During February-April COVID Crisis

Written by Customer Service on June 12, 2020. Posted in Public Companies.

MARTINSVILLE, Va., June 12, 2020 (GLOBE NEWSWIRE) — Hooker Furniture Corporation (NASDAQ-GS: HOFT) today reported its preliminary financial results for its fiscal 2021 first quarter.“COVID-19 had a material impact on our financial performance in the fiscal 2021 first quarter and on the market valuations, discount rates and other inputs used in our intangibles valuation analysis,” said Paul B. Toms, Jr. Chairman and CEO. “Consequently and despite having completed a similar intangible asset valuation during our fiscal 2020 fourth quarter, we determined that another intangible asset valuation was appropriate given our performance and changing market dynamics. Given the effort and complexity involved in this project, we need additional time to complete this analysis,” he concluded. The Company’s preliminary unaudited financial results...

Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease

Written by Customer Service on June 12, 2020. Posted in Public Companies.

CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical, proof-of-concept study of EDIT-301. EDIT-301 is being developed as a potentially best-in-class, durable medicine to treat sickle cell disease. EDIT-301 contains CD34+ hematopoietic stem cells from sickle patients that are edited at the HBG1/2 promoter in the beta-globin locus using Cas12a (also known as Cpf1) to induce fetal hemoglobin (HbF) where HbF-inducing mutations occur naturally. The Company reported the data at the 25th Congress of the European Hematology Association being held virtually.In vitro studies with EDIT-301 revealed several desirable properties. In particular, editing was highly efficient and reproducible, with approximately 90 percent editing in...

Cross Laminated Timber Market to Rise at 13.7% CAGR till 2027; Product Applications across Diverse Industry Verticals Will Aid Growth, says Fortune Business Insights™

Written by Customer Service on June 12, 2020. Posted in Mergers And Acquisitions.

Pune, June 12, 2020 (GLOBE NEWSWIRE) — The global cross laminated timber market size is projected to reach USD 2,062.2 million by the end of 2027. The increasing construction and building activities will create several growth opportunities for the companies operating in the market. According to a report published by Fortune Business Insights, titled “Cross Laminated Timber Market Size, Share & Industry Analysis, By Bonding Technology (Adhesive Bonded and Mechanically Fastened), By Application (Residential Buildings, Non-Residential Buildings, and Others), and Regional Forecast, 2020-2027,” the market was worth USD 756.9 million in 2019 and will exhibit a CAGR of 13.7% during the forecast period, 2020-2027.Browse Summary of This Research Report with Detailed Table of Content: https://www.fortunebusinessinsights.com/cross-laminated-timber-clt-market-102884COVID-19...

Qingke Announces New Chief Operating Officer

Written by Customer Service on June 12, 2020. Posted in Public Companies.

SHANGHAI, China, June 12, 2020 (GLOBE NEWSWIRE) — Q&K International Group Limited (NASDAQ: QK) (“Qingke” or the “Company”), a leading technology-driven long-term apartment rental platform in China, today announced that Mr. Chengcai Qu has been appointed as the chief operating officer of the Company, effective June 12, 2020.Mr. Chengcai Qu has served as Qingke’s director since 2020 and vice president since 2013. Prior to joining Qingke, Mr. Qu was a director of the office of public relations at Antai School of Economics and Management of Shanghai Jiao Tong University from November 2006 to November 2013. From June 2004 to October 2006, Mr. Qu was a newspaper reporter specializing in business and management. Mr. Qu received a bachelor’s degree in literature from Shanghai University of Finance and Economics in 2004, and a master’s...

Annual general meeting in Dampskibsselskabet NORDEN A/S

Written by Customer Service on June 12, 2020. Posted in Public Companies.

ANNOUNCEMENT NO. 15 – 12 JUNE 2020Attached as separate PDF file, please find Chairman of the Board of Directors Klaus Nyborg’s oral report in full from NORDEN’s annual general meeting, which is held today 12 June 2020 at 11 am CEST.The Chairman’s report and the accompanying presentation (the presentation is only available in Danish) will also be made available at www.ds-norden.com from approximately 11 am CEST. A webcast (in Danish) from the annual general meeting will also be made available today after the general meeting.Kind regardsDampskibsselskabet NORDEN A/SBoard of DirectorsFor further information:Martin Badsted, CFO, tel.: +45 3315 0451AttachmentsNo. 15 Chairman’s Report – Annual General Meeting 2020Chairman’s report 2020

Generalforsamling i Dampskibsselskabet NORDEN A/S

Written by Customer Service on June 12, 2020. Posted in Public Companies.

SELSKABSMEDDELELSE NR. 15 – 12. JUNI 2020Vedhæftet som separat PDF-fil følger i sin helhed bestyrelsesformand Klaus Nyborgs mundtlige beretning ved den ordinære generalforsamling i NORDEN i dag 12. juni 2020 kl. 11.Formandens beretning og den tilhørende præsentation, som kun foreligger på dansk, vil også være tilgængelig på www.ds-norden.com fra ca. kl. 11. Her vil en webcast (på dansk) af generalforsamlingen også blive tilgængelig i dag efter generalforsamlingen er afsluttet.Med venlig hilsenDampskibsselskabet NORDEN A/SBestyrelsenYderligere oplysninger:Martin Badsted, Finansdirektør, tlf.: +45 3315 0451 Vedhæftede filerNr. 15 Formandens beretning – ordinær generalforsamling 2020Formandens beretning 2020

Month: June 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals